Published in Semin Immunol on June 09, 2008
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol (2009) 1.40
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol (2010) 1.29
New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv (2009) 1.29
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther (2012) 1.21
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol (2009) 1.16
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol (2015) 1.05
Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res (2010) 1.05
Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. J Neurooncol (2010) 1.03
Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol (2012) 1.02
Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics (2009) 1.00
Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol (2010) 0.97
Targeted therapies for malignant glioma: progress and potential. BioDrugs (2009) 0.97
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res (2011) 0.96
Current vaccine trials in glioblastoma: a review. J Immunol Res (2014) 0.96
Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res (2010) 0.95
Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med (2014) 0.92
Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am (2010) 0.91
Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model. J Immunol (2011) 0.91
Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas. PLoS One (2014) 0.90
Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol (2012) 0.90
Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) (2013) 0.90
Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am (2010) 0.87
The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol (2010) 0.87
Improving seroreactivity-based detection of glioma. Neoplasia (2009) 0.86
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics (2012) 0.85
Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours. PLoS One (2013) 0.84
Glioma stem cells and immunotherapy for the treatment of malignant gliomas. ISRN Oncol (2013) 0.84
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs (2009) 0.83
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol (2011) 0.82
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid (2012) 0.81
Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles. PLoS One (2013) 0.81
Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy (2013) 0.81
Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer. Part Part Syst Charact (2015) 0.80
Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma. J Immunol Res (2014) 0.79
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Brain Tumor Genetic Modification Yields Increased Resistance to Paclitaxel in Physical Confinement. Sci Rep (2016) 0.77
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
A pan-cancer analysis of alternative splicing events reveals novel tumor-associated splice variants of matriptase. Cancer Inform (2014) 0.76
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment. Front Pharmacol (2016) 0.75
Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients. Oncol Lett (2016) 0.75
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Front Pharmacol (2016) 0.75
A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme. World J Exp Med (2011) 0.75
The value of EGFRvIII as the target for glioma vaccines. Am Soc Clin Oncol Educ Book (2014) 0.75
Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery (2014) 0.75
In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the φ index. Clin Cancer Res (2017) 0.75
Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. Biomed Res Int (2017) 0.75
Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int J Nanomedicine (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Genetic instabilities in human cancers. Nature (1998) 22.76
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med (1996) 8.54
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 8.23
Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med (2001) 7.86
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 6.58
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 4.90
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res (2000) 4.79
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
A mutator phenotype in cancer. Cancer Res (2001) 4.41
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol (2003) 4.17
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A (1990) 3.70
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res (1995) 3.04
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res (2007) 3.02
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res (1996) 3.00
CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol (2000) 2.98
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol (1988) 2.74
Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol (1988) 2.70
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res (1995) 2.67
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol (1990) 2.24
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med (1972) 2.20
Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A (1999) 2.19
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. J Exp Med (1987) 2.14
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
The promise of cancer vaccines. Nat Rev Cancer (2004) 1.92
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res (1997) 1.89
Animal models. Ann Neurol (1994) 1.88
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol (2004) 1.85
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res (1993) 1.82
Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol (1989) 1.79
T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol (1993) 1.74
Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol (1986) 1.74
Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J (1997) 1.72
The makings of a tumor rejection antigen. Immunity (1999) 1.71
Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol (1984) 1.68
Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene (2004) 1.66
Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens. Immunology (1994) 1.65
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J (1987) 1.59
Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res (2001) 1.59
Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci (2003) 1.58
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res (2002) 1.54
A study of the chemical nature of components of bovine white matter effective in producing allergic encephalomyelitis in the rabbit. J Exp Med (1954) 1.48
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res (2001) 1.47
Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene (1996) 1.45
A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science (2006) 1.44
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res (2006) 1.41
Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem (2000) 1.39
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs (2009) 2.90
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Retracted Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2010) 2.24
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol (2012) 2.02
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One (2011) 2.00
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res (2007) 1.91
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov (2004) 1.74
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 1.67
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Mutant metabolic enzymes are at the origin of gliomas. Cancer Res (2009) 1.66
Medical diagnostic radiation exposures and risk of gliomas. Radiat Res (2011) 1.64
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res (2006) 1.63
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res (2012) 1.63
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res (2008) 1.62
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood (2011) 1.54
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol (2009) 1.53
Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem (2003) 1.52
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res (2012) 1.46
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res (2013) 1.46
Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther (2011) 1.45
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res (2006) 1.41
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget (2014) 1.40
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40